Bladder cancer | Editor-in-chief: Maria De Santis

Management of M0 muscle-invasive bladder cancer beyond radical cystectomy

Background

Optimal management of MIBC goes beyond performing radical cystectomy (RC) and requires the involvement of a multidisciplinary team. In this module, all patients have urothelial carcinoma (UCa) in absence of (extensive) variant histology.

Educational Objective

Gain insight on when to use neoadjuvant chemotherapy, on factors that impact the decision on bladder preserving treatment and on RC and on when to use adjuvant chemotherapy or adjuvant radiation therapy (RT).

Specialty

Urology, medical oncology, radiation oncology

Target Audience

CME (basic), Residents (senior)

Latest update

June, 2019

--NEW-- BCG or early cystectomy? Challenges in high risk NMIBC

Background

High-risk NMIBC includes T1 tumours, G3 (high grade) tumours, carcinoma in situ (CIS) or multiple, recurrent and large (>3 cm) TaG1/G2/LG tumours, according to the EAU guidelines.

Educational Objective

Gain insight into indications for second resection and for Bacillus Calmette-Guérin (BCG) therapy; treatment options after BCG failure and recurrence after BCG therapy; indications for radical cystectomy in NMIBC.

Specialty

Urology, medical oncology

Target Audience

CME (basic, intermediate), Residents (senior)

Latest update

July 2019

--NEW-- Variant histology = radical cystectomy, right?

Background

Histological variants of UCa and non-urothelial bladder cancer types account for up to 25% of all bladder cancers. As guidelines mainly focus on pure UCa, and scientific data on variants is scarce, recommendations are mainly based on expert opinion.

Educational Objective

Gain insight in the management of urothelial tumours with variant histology and of different types of tumours of the urothelial tract. Appreciate that not all variants/types are created equally.

Specialty

Urology (medical oncology, radiation oncology)

Target Audience

CME (intermediate-advanced), Residents (senior)

Latest update

July 2019

--NEW-- New hope for patients progressing after 1st-line treatment for mUCa

Background

The treatment algorithm has changed the last years. As recent as 2017, 2nd-line therapy for mUCa was either: re-exposure to 1st-line platinum-based therapy, vinflunine, taxane, best supportive care or clinical study. Luckily, times are changing...

Educational Objective

Gain insight in new treatment options for a patient population with very few options in the past

Specialty

Medical oncology, urology, clinical oncology, (radiation oncology)

Target Audience

CME (intermediate-advanced) | Residents (senior)

Latest update

August 2019

--NEW--It’s getting personalised: 1st-line treatment for mUCa

Background

Standard 1st-line treatment for mUCa patients has been platinum-based chemotherapy for many years. The advent of immunotherapy broadens the treatment landscape, especially for cisplatin-ineligible patients, and paves the way for more personalised medicine

Educational Objective

Appreciate the different treatment options for cisplatin eligible and ineligible patients. Gain insight on other factors that have an impact on treatment decision, e.g. (time since) previous systemic therapy in the M0 setting; ECOG PS and PD-L1 status

Specialty

Medical oncology, urology, clinical oncology, (radiation oncology)

Target Audience

CME: intermediate-advanced | Residents: senior

Latest update

August 2019